Month: August 2024

Mol Genet Metab Rep. 2024 Jul 9;40:101117. doi: 10.1016/j.ymgmr.2024.101117. eCollection 2024 Sep. ABSTRACT BACKGROUND: Biochemical testing is a common first-tier approach in the setting of …

Res Pract Thromb Haemost. 2024 Jun 21;8(5):102482. doi: 10.1016/j.rpth.2024.102482. eCollection 2024 Jul. ABSTRACT BACKGROUND: Real-world experience with efmoroctocog alfa (a recombinant factor [F]VIII Fc fusion …

Rinsho Ketsueki. 2024;65(7):668-675. doi: 10.11406/rinketsu.65.668. ABSTRACT Chimeric antigen receptor-transduced autologous T (CAR-T) cell therapy targeting CD19 has revolutionized the treatment of CD19-positive hematological tumors, including …

Rinsho Ketsueki. 2024;65(7):652-661. doi: 10.11406/rinketsu.65.652. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment paradigm for refractory/relapsed (R/R) hematologic malignancies, with six products …

Rinsho Ketsueki. 2024;65(7):662-667. doi: 10.11406/rinketsu.65.662. ABSTRACT Chimeric antigen receptor T-cell therapy (CAR-T-cell therapy) has revolutionized the treatment of relapsed and refractory hematological malignancies. Targeting of …

Pediatr Dermatol. 2024 Aug 4. doi: 10.1111/pde.15715. Online ahead of print. ABSTRACT This case describes a pediatric patient with a history of ichthyosis vulgaris and …

Rinsho Ketsueki. 2024;65(7):634-643. doi: 10.11406/rinketsu.65.634. ABSTRACT Chimeric antigen receptor (CAR)-T cell therapy is among the most promising immunotherapies for hematological malignancies and can be used …

Afr J Reprod Health. 2024 Jul 31;28(7):54-60. doi: 10.29063/ajrh2024/v28i7.6. ABSTRACT The aim of this study is a virtual reality versus low level simulation in newborn …